PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer
BackgroundAlthough immune checkpoint blockade (ICB) therapy has transformed the therapeutic landscape for ovarian cancer (OC), the predictive utility of immune checkpoint (IC) expression signatures in stratifying clinical outcomes requires further systematic interrogation.MethodsTranscriptomic profi...
Saved in:
| Main Authors: | Yifan Wu, Cunte Chen, Yingwen Cui, Ruoyao Zou, Yaoxiang Yang, Fengjie Sun, Yanzi Du, Peipei Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1656242/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model
by: Felipe F. Lamenza, et al.
Published: (2025-12-01) -
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma
by: Melanie Wiecken, et al.
Published: (2025-12-01) -
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
by: RuiXin Zheng, et al.
Published: (2025-09-01) -
Immune checkpoint blockers and ovarian cancer
by: Chinmoy K Bose
Published: (2017-01-01)